Retinoic acid receptor activating peptide and Cosmetic composition including the same
A peptide with specific sequences activates retinoic acid receptors to improve skin wrinkles, whiten, and regenerate skin, addressing the inefficacy and side effects of conventional substances.
Patent Information
- Application Number
- KR1020230121129
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2023-09-12
- Publication Date
- 2026-11-06
- Estimated Expiration
- 2043-09-12
AI Technical Summary
Conventional substances that control retinoic acid receptors are either insufficiently effective or cause side effects due to chemical synthesis.
A peptide with specific amino acid sequences (SEQ ID NO. 1 or 2) is developed to activate retinoic acid receptors, improving skin wrinkles, whitening, and regeneration.
The peptide enhances skin wrinkle improvement, whitening, and regeneration by activating retinoic acid receptors, demonstrating increased physical binding and transcriptional activity, and reducing melanin synthesis.
Smart Images

Figure 112023100787541-PAT00001_ABST
Abstract
Description
Technology Field
[0001] The present invention relates to a peptide that activates retinoic acid receptors and a cosmetic composition using the same. Background Technology
[0002] Retinoic acid receptors are receptors necessary for the action of retinoic acid, which can be considered the active form of vitamin A; after binding to retinoic acid, they bind to specific locations on genes to control their transcription. Furthermore, these retinoic acid receptors are known to be involved in skin melanin production, wrinkle formation, and anti-aging (skin regeneration) functions.
[0003] Accordingly, as described in the patent document below, a substance is being developed to treat related diseases by controlling the action of the above-mentioned retinoic acid receptor.
[0004] <Patent Literature>
[0005] Patent Publication No. 10-1990-07000601 (Published Aug. 16, 1990) "Retinoic acid receptor composition and method for preparing the same"
[0006] However, conventional substances that control the action of retinoic acid receptors are either insufficiently effective or, since most are chemically synthesized, pose a problem that may cause side effects when used. The problem to be solved
[0007] The present invention has been devised to solve the above-mentioned problems,
[0008] The present invention aims to provide a peptide that activates retinoic acid receptors, which can be used for wrinkle improvement, skin whitening, and skin regeneration (anti-aging), and a cosmetic composition using the same. means of solving the problem
[0009] The present invention is implemented by an embodiment having the following configuration to achieve the aforementioned objective.
[0010] According to one embodiment of the present invention, the peptide according to the present invention is characterized by being composed of the amino acid sequence of SEQ ID NO. 1 or 2.
[0011] According to another embodiment of the present invention, the peptide according to the present invention is characterized by activating a retinoic acid receptor.
[0012] According to another embodiment of the present invention, the peptide according to the present invention is characterized by being used for skin whitening, wrinkle improvement, or skin regeneration.
[0013] According to another embodiment of the present invention, the cosmetic composition according to the present invention is characterized by comprising a peptide composed of the amino acid sequence of SEQ ID NO. 1 or 2.
[0014] According to another embodiment of the present invention, the peptide according to the present invention is characterized by comprising a peptide composed of the amino acid sequence of SEQ ID NO. 1 or 2.
[0015] According to another embodiment of the present invention, a cosmetic composition for skin whitening according to the present invention is characterized by comprising a peptide composed of an amino acid sequence.
[0016] According to another embodiment of the present invention, a cosmetic composition for improving skin wrinkles according to the present invention is characterized by comprising a peptide composed of the amino acid sequence of SEQ ID NO. 1 or 2. Effects of the invention
[0017] The present invention can achieve the following effects through the previously described embodiment.
[0018] The present invention has the effect of improving wrinkles, whitening, and regeneration (anti-aging) of the skin by activating retinoic acid receptors using a peptide composed of the amino acid sequence of SEQ ID NO. 1 or 2. Brief explanation of the drawing
[0019] FIG. 1 is a graph showing the effect of a peptide according to one embodiment of the present invention on the physical binding of RAR and RXR. FIG. 2 is a graph showing the effect of a peptide according to one embodiment of the present invention on the physical binding of P53 and POLII. FIG. 3 is a graph showing the effect of a peptide according to one embodiment of the present invention on the induction of intracellular collagen synthesis. Specific details for implementing the invention
[0020] Hereinafter, a retinoic acid receptor-activating peptide according to the present invention and a cosmetic composition containing the same will be described in detail with reference to the attached drawings. Unless otherwise specifically defined, all terms in this specification have the same general meaning as understood by a person skilled in the art to which the present invention pertains, and if there is a conflict with the meaning of a term used in this specification, the definition used in this specification shall prevail. Furthermore, detailed descriptions of known functions and configurations that may unnecessarily obscure the essence of the present invention are omitted. Throughout the specification, when a part is described as "comprising" a certain component, this means that, unless specifically stated otherwise, it does not exclude other components but may include additional components.
[0022] One embodiment of the present invention relates to a peptide that activates a retinoic acid receptor, wherein the peptide is characterized by having the amino acid sequence of SEQ ID NO. 1 (Ile-Gln-Glu-Met) or SEQ ID NO. 2 (Thr-Val-Glu-Phe). The peptide can improve the condition of the skin by activating the retinoic acid receptor. Specifically, the peptide can promote the improvement of skin wrinkles, whitening, and skin regeneration (anti-aging). The peptide can be used in cosmetic compositions, therapeutic compositions, etc.
[0024] Another embodiment of the present invention relates to a cosmetic composition comprising a peptide having the amino acid sequence of SEQ ID NO. 1 or 2, wherein the cosmetic composition can improve wrinkles, whiten, and regenerate skin (anti-aging). Various known ingredients capable of providing formulation stability and additional skin condition improvement effects may be added to the cosmetic composition.
[0026] The present invention will be explained in more detail below through examples. However, these examples are intended only to explain the invention in more detail and do not limit the scope of the invention.
[0028] <Example 1> Synthesis of Peptides
[0030] The peptides of SEQ ID NOs 1 and 2 listed in Table 1 below were synthesized using the FMOC solid-phase method with an automated synthesizer (PeptrEx-R48, Peptron, South Korea). The synthesized peptides were purified and analyzed using reverse-phase high-speed liquid chromatography (Prominence LC-20AB, Shimadzu, Japan) with a C18 analysis RP column (Shiseido capcell pak), and identified using a mass spectrometer (HP 1100 Series LC / MSD, Hewlett-Packard, USA).
[0031] Peptide names Sequence number amino acid sequence Raragin A Sequence No. 1 Ile-Gln-Glu-Met Raragin B Sequence No. 2 Thr-Val-Glu-Phe
[0033] <Example 2> Verify whether the peptide of Example 1 activates the retinoic acid receptor to increase the physical binding of RAR and RXR.
[0035] 1. Retinol regulates the transcription of target DNA by inducing the binding of the retinoic acid receptor (RAR) and the retinoid X receptor (RXR). To determine whether the peptide of Example 1 activates the binding of RXR / RAR, the effect on the physical binding of RAR and RXR was evaluated through an in situ PLA (proximity ligation assay) method.
[0036] 2. Specifically, 4.5 × 10⁻⁶ in each well of the 24-well microplate 4 HaCaT cells (human keratinocytes) were seeded into DMEM serum medium and cultured for 24 hours in a 37°C, 5% CO2 incubator. Then, each of the peptides from Example 1 was treated, and the cells were incubated under the same conditions for 30 minutes. The concentration of each peptide in the medium was set to 1 and 10 μM, and untreated cells were used as a control. Subsequently, the cells in each well were washed with PBS, fixed by treatment with 2% formaldehyde for 15 minutes, and then treated with 0.1% TritonX-100 for 5 minutes to increase antibody permeability into the cells. Anti-RAR monoclonal antibodies (Santa Cruz, USA) and anti-RXR polyclonal antibodies (Santa Cruz, USA) were added, and a PLA probe was added using an in situ PLA kit (Sigma-Aldrich), followed by hybridization, ligation, amplification, and mounting steps.
[0037] 3. Subsequently, the physical interaction between RAR and RXR antibodies was quantified by measuring the luminescence signals (PLA signals) detected in each cell using a fluorescence microscope (logosbio / CelenaS, Korea), and the results are shown in Figure 1.
[0038] 4. Looking at Figure 1, it can be seen that when treated with Raragin A to B of Example 1, the physical binding of RAR and RXR is increased compared to the untreated control group. That is, Raragin A to B activate RAR, thereby increasing the physical binding of RAR and RXR and providing efficacy similar to retinol.
[0040] <Example 3> Verify whether the peptide of Example 1 activates the retinoic acid receptor to increase the physical binding of P53 and POLII.
[0042] 1. To determine whether the peptide of Example 1 increases the transcriptional activity of P53, which is associated with anti-aging of cells, the effect on the physical binding of P53 and POLII (RNA Polymerase II) was evaluated through the in situ PLA (proximity ligation assay) method after treating cells with the peptide of Example 1.
[0043] 2. Specifically, 4.5 × 10⁻⁶ in each well of the 24-well microplate 4HaCaT cells (human keratinocytes) were seeded into DMEM serum medium and cultured for 24 hours in a 37°C, 5% CO2 incubator. Then, each of the peptides from Example 1 was treated, and the cells were incubated for 30 minutes under the same conditions. The concentration of each peptide in the medium was set to 1 and 10 μM, and untreated cells were used as a control. Subsequently, the cells in each well were washed with PBS, fixed by treatment with 2% formaldehyde for 15 minutes, and then treated with 0.1% TritonX-100 for 5 minutes to increase antibody permeability into the cells. Anti-P53 polyclonal antibody (CST, USA) and anti-POLII monoclonal antibody (Santa Cruz, USA) were added, and a PLA probe was added using an in situ PLA kit (Sigma-Aldrich), followed by hybridization, ligation, amplification, and mounting steps.
[0044] 3. Subsequently, the physical interaction between P53 and POLII antibodies was quantified by measuring the luminescence signals (PLA signals) detected in each cell using a fluorescence microscope (logosbio / CelenaS, Korea), and the results are shown in Figure 2.
[0045] 4. Looking at Figure 2, it can be seen that when treated with Raragin A to B of Example 1, the physical binding between P53 and POLII is increased compared to the untreated control group. That is, it can be seen that Raragin A to B increase the transcriptional activity of P53 and prevent cell aging.
[0047] <Example 4> Evaluation of the effect of the peptide of Example 1 on intracellular collagen synthesis
[0049] 1. Immunofluorescence analysis was performed to evaluate the effect of the peptide of Example 1 on intracellular collagen synthesis.
[0050] 2. Specifically, 4.5 x 10⁶ in each well of the 24-well microplate 4 Canine human dermal fibroblasts were seeded with medium (CEFOgro Human MSC Growth Medium) and cultured for 24 hours in a 37°C, 5% CO2 incubator. Subsequently, each peptide of Example 1 was treated, and the cells were incubated under the same conditions for 24 hours. The concentration of each peptide in the medium was set to 1 and 10 μM, and a control group with no treatment and a group treated with 1 μM Retinol were used. Cells in each well were washed with PBS and fixed by treatment with 4% formaldehyde for 15 minutes, followed by treatment with 0.1% TritonX-100 for 5 minutes to increase antibody permeability into the cells. Cells were washed with PBS solution and treated with anti-COL1A2 polyclonal antibody (Santa Cruz, CA, USA) for 1 hour, followed by treatment with mouse anti-goat IgG-FITC for 40 minutes. Phalloidin-Rhodamin was treated for 40 minutes to stain the cytoskeleton. For cell nucleus staining, the cells were mounted with a reagent containing DAPI, observed using a fluorescence microscope (Logosbio / CelenaS, Korea), and quantified using the program (NIS-Eliments-3.1). The results are shown in Figure 3.
[0051] 3. As shown in Fig. 3, it can be seen that when treated with Laragin A to B of Example 1, collagen synthesis was significantly increased compared to the untreated control group.
[0053] <Example 5> Evaluate whether the peptide of Example 1 inhibits melanin synthesis in cells
[0055] 1. To evaluate the effect of the peptide of Example 1 on melanin synthesis in cells, the peptide of Example 1 was evaluated to determine whether it inhibited melanin synthesis under conditions where melanocytes were stimulated with α-MSH to promote melanin synthesis.
[0056] 2. Specifically, 1×10⁻⁶ in each well of a 6-well microplate 5 B16F10 (mouse melanocytes) were inoculated into DMEM serum medium and cultured for 24 hours in a 37°C, 5% CO2 incubator. Subsequently, 100 nM of α-Melanocyte Stimulating Hormone (α-MSH) and each of the peptides from Example 1 were added to the medium, and the cells were incubated under the same conditions for 72 hours. The concentrations of each peptide in the medium were set to 1 and 10 μM. Control groups included no treatment, α-MSH alone, and Retinol 1 μM. Afterward, to measure the amount of extracellular melanin, the supernatant was taken, and the absorbance of the melanin released into the medium was measured at 400 nm. To measure the amount of intracellular melanin, the cells were washed with PBS after removing the medium, lysed in 1 M NaOH at 60°C for 30 minutes, and the absorbance was measured at 400 nm. The amount of free melanin and the amount of intracellular melanin were quantified by absorbance, and the results are shown in Table 2.
[0057] 3. Looking at Table 2, it can be seen that when treated with Raragin A to B of Example 1, the increase in melanin induced by α-MSH stimulation was reduced compared to the untreated control group. In other words, it can be confirmed that the peptide of Example 1 has a whitening effect.
[0058] Unprocessed α-MSH α-MSH + Retinol (1uM) α-MSH+Raragin A(1uM) A(10uM) B(1uM) B(10uM) Amount of Melanin (of Control) 100 118 114 111 107 109 106
[0060] <Example 6> Skin patch test of the cosmetic composition containing the peptide of Example 1
[0062] 1. Cosmetic compositions were prepared by adding each of the peptides prepared in Example 1 to a commercially available solubilized ampoule base at a concentration of 50 ppm. Cosmetic composition 1 represents a solubilized ampoule base without the peptide of Example 1 added, cosmetic composition 2 represents the case where Raragin A is added, and cosmetic composition 3 represents the case where Raragin B is added.
[0063] 2. Nine adults aged 20 to 60 were subjected to the application of the same amount of the above cosmetic composition to their faces every morning and evening for 6 weeks. After 6 weeks, a sensory evaluation of skin improvement was conducted, and the results are shown in Table 3. The sensory evaluation items included whether there was skin irritation, the degree of wrinkle improvement, the degree of skin tone improvement (whitening), and the degree of skin regeneration (evaluated by comprehensively considering factors such as increased elasticity and reduced scars). Participants were asked to rate the condition as 5 points if it was good and 0 points if it was poor.
[0064] 3. Looking at Table 3, it can be seen that cosmetic compositions 2 and 2 receive higher scores than cosmetic composition 1, indicating that the peptide of Example 1 can be used in cosmetic compositions to improve wrinkle reduction, skin whitening, and skin regeneration effects.
[0065] Cosmetic composition 1 2 3 Whether or not there is skin irritation X X X Wrinkle improvement 3.2 4.1 4.3 skin tone improvement 3.1 4.3 4.4 Skin regeneration 2.9 3.9 4.3
[0067] Although the applicant has described preferred embodiments of the present invention above, such embodiments are merely examples of implementing the technical concept of the present invention, and any modification or alteration that implements the technical concept of the present invention should be interpreted as falling within the scope of the present invention.
Claims
Claim 1 A peptide composed of the amino acid sequence of SEQ ID NO. 1 or 2. Claim 2 delete Claim 3 delete Claim 4 A cosmetic composition characterized by comprising a peptide composed of the amino acid sequence of SEQ ID NO. 1 or 2. Claim 5 delete Claim 6 delete Claim 7 A cosmetic composition for improving skin wrinkles characterized by comprising a peptide composed of the amino acid sequence of SEQ ID NO. 1 or 2.
Citation Information
Patent Citations
Composition of collagen peptides for cosmetics and method thereof
KR1020080063711A
Anti-aging peptide composition and cosmetic composition that prevents cells aging and improves wrinkles.
KR1020180108990A
